Navigation Links
Labopharm amends debt facility agreement with Hercules
Date:6/25/2009

structuring of the Canadian asset-backed commercial paper, which amount the Company can, under certain conditions, repay at maturity by delivering the notes to the bank.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets, and Australia, among others. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
2. Labopharm Reports Results for First Quarter Fiscal 2009
3. Labopharm announces details for first quarter results conference call and annual meeting
4. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
5. Labopharm to present at Cowen 29th Annual Health Care Conference
6. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
7. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
8. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
9. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
10. Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
11. Labopharm Comments on Recent Trading Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 26, 2014 Yisrayl Hawkins, Pastor at The ... letter in light of the Ferguson, Missouri unrest. Yisrayl starts ... unrest and explains why it has only increased. , ... even created. He says there is a very specific reason ... says there is a set of rules, or Laws that ...
(Date:12/26/2014)... PA (PRWEB) December 26, 2014 Pentec ... Work in the state of Pennsylvania for 2014. The ... first statewide programs of its kind in the country. ... Foundation, the Pennsylvania Department of Community and Economic Development, ... Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... The click strand woven ... and durability. Today, the business announces a click ... until Jan. 30, 2015. , Click strand woven ... BambooFlooringChina.com is a well-known brand in the bamboo ... find a reliable bamboo flooring supplier. , “We ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses ... selection of black one-shoulder cocktail dresses . In addition, ... available at discounted prices, up to 70% off. ... three weeks only. You know, we have thousands of frequent ... our new items can visit our website for more details. ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Not drying your hands thoroughly after washing them, could increase ... a conventional electric hand dryer could be a contributing factor. ... on their clothes instead, but hand-hygiene is a key part ... very important part of the process. A study by ...
... HealthDay Reporter , TUESDAY, Sept. 7 (HealthDay News) -- The ... infection in her arm. When doctors used ultrasound on the ... under her skin, including a paper clip, a screw from ... The teen had engaged in "self-embedding," an extreme form ...
... University has been a issued a patent for a plentiful ... the umbilical cord. The patent addresses procedures to isolate, ... the substance that cushions blood vessels in the umbilical cord. ... different than those obtained from the blood cells in umbilical ...
... building on skills and strengths, and getting strangers to work ... Now, a pilot study of six families living in a ... cash could fuel such cooperation and produce overlapping benefits. ... have assets as well as significant health-care needs, says Alfonso ...
... who used multivitamins during and after being treated with post-surgical ... or their dying from it, according to researchers at Dana-Farber ... III colon cancer characterized as cancer in the large ... lymph nodes -- the researchers found that while multivitamin use ...
... Medicine have discovered a major mechanism underlying the development ... help researchers find new therapies to treat chronic pain, ... use. The findings are published in the July 20th ... to morphine after chronic administration has been a persistent ...
Cached Medicine News:Health News:Is hand washing enough to stop the spread of disease? 2Health News:'Self-Embedding' Takes Teen Self-Injury to the Extreme 2Health News:'Self-Embedding' Takes Teen Self-Injury to the Extreme 3Health News:K-State receives patent for noncontroversial source of stem cells 2Health News:For migrant workers, community cooperation builds on individual strengths 2Health News:For migrant workers, community cooperation builds on individual strengths 3Health News:Multivitamin use doesn't impact colon cancer outcomes 2Health News:Mount Sinai researchers find new target to improve pain management 2
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ... corporate offices in Aliso Viejo , ... due to the tremendous growth and worldwide expansion, a ... of patented SnoreRx, the anti snore cure have exceeded ... said, "We are now in 23 countries and ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "Investment Analysis of the ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the US medical device sector identifies the key ... venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... ISIS ) announces the following webcast: What: , ... Wednesday, April 25, 2012 at 12:00 p.m. ET / 9:00 a.m. PT ... , Live on the Internet. Simply log onto our Web ... live event, a replay of the webcast will be available for a ...
... -   Retrospective sub-analyses from ADVANCE, ILLUMINATE and ... for the Study of the Liver (EASL) 2012 - ... for INCIVO (telaprevir) from Phase 3 retrospective sub-analyses at the ... of the Liver (EASL) in Barcelona.  The data shows that ...
Cached Medicine Technology:INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 2INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 3INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 4INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 5INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 6INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 7
Designed to have a shock-absorbing force, providing less bounce or wasted force....
Straight curette with hollow handle and round cup....
Perisoteal rasp for elevating, dissecting, and scraping....
9 inch sharp bone hook with grip handle....
Medicine Products: